Amylin to lay off 340 employees in San Diego

11/10/2008 | Bloomberg Businessweek · San Diego Business Journal

Amylin Pharmaceuticals announced that it is cutting its San Diego work force by 25% to reduce expenses by more than $100 million next year. The move comes a week after the FDA rejected Amylin's data on a once-weekly formulation of Byetta, a treatment for Type 2 diabetes.

View Full Article in:

Bloomberg Businessweek · San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park